Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Worst Performers Over Last Quarter
Oct 06, 2008 02:19 AM
- Technical Analysis: Charts With Solid Risk/Reward
Sep 11, 2008 02:13 AM
- Short Picks for Wednesday
Aug 28, 2008 02:09 AM
- Analyst Comments: SABESP, Superior Industries, Bellus Health, Amerigroup, Sonic Innovations, Petrobras, Wal-Mart, Eli Lilly
Aug 14, 2008 05:56 PM
- Special Report: Hit the BRICs for a Global-Investing Double Play
Aug 01, 2008 02:08 PM
- Two Big Reasons to Remain Bullish on Brazilian Stocks
Jul 11, 2008 11:40 AM
- Brazil Economy Expanded 5.8% in 1Q; Central Bank Likely to Raise Rates Again
Jun 10, 2008 06:01 PM
- Analyst Comments: SABESP, Sycamore, Triumph Group
Jun 03, 2008 01:56 AM
- The 10 Best Investments Over the Last 7+ Years
May 18, 2008 01:58 AM
- Is Brazil 'Investment Grade' for Investor's Money, Too?
May 14, 2008 07:05 PM
- Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2
Oct 06, 2008 07:01 AM
- Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2
Oct 06, 2008 07:00 AM
- SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Sep 16, 2008 08:53 AM
- Sabesp Announces Tariff Readjustment
Aug 11, 2008 05:50 PM
- SABESP's Net Revenue Grows 4.5% in 2Q08
Aug 08, 2008 07:11 PM
- SemBioSys announces second quarter 2008 financial and operational results
Aug 05, 2008 07:02 AM
- SemBioSys announces second quarter 2008 financial and operational results
Aug 05, 2008 07:00 AM
- Sabesp Announces Dividend Payment in the Form of Interest on Own Capital
Aug 01, 2008 08:52 PM
- SemBioSys submits IND for safflower-produced insulin to U.S. FDA
Jul 29, 2008 07:00 AM
- Botaneco announces $4,000,000 financing
Jun 30, 2008 07:01 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
SBS
|
Compare to S&P
|
| YTD |
-45.85 %
|
-27.67 %
|
| 4 Weeks |
-36.23 %
|
-27.93 %
|
| 12 Weeks |
-49.58 %
|
-43.15 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -0.01 %
|
|
EPS Growth in Last Year: 190.91 %
|
|
Sales Growth in Last Quarter: 3.21 %
|
|
Sales Growth in Last Quarter: 16.22 %
|
|
|
